Justin Paul Kline MD

Associate Professor of Medicine, University of Chicago Medicine

Summary

Dr. Justin Kline is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Chicago Pritzker School of Medicine and has been in practice 16 years. He specializes in hematologic oncology and is experienced in hematologic oncology and stem cell transplantation.

University of ChicagoFellowship, Hematology and Medical Oncology, 2004 - 2007
University of ChicagoResidency, Internal Medicine, 2001 - 2004
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2001

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

Two-Stage CD8CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma.
Guoshuai Cao, Yifei Hu, Tony Pan, Erting Tang, Nick Asby
Biorxiv. 2025-03-15
1 citations
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.
Sravya Tumuluru, James K Godfrey, Alan Cooper, Jovian Yu, Xiufen Chen
Blood. 2025-01-27
Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity.
Yan-Hong Cui, Jiangbo Wei, Hao Fan, Wenlong Li, Lijie Zhao
Proceedings of the National Academy of Sciences of the United States of America. 2024-12-17

Journal Articles

CD8α+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell Fates
Justin Kline, MD, The Journal of Immunology
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine

Abstracts/Posters

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL
Justin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes
Justin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
Justin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Emerging Role of Immune Checkpoint Blockade in the Treatment of Refractory/Relapsed Hodgkin and Non-Hodgkin Lymphoma
60th American Society of Hematology Annual Meeting - 11/30/2018

ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
New Analysis of the Tumor Microenvironment Reveals 3 Subtypes in Large B-cell Lymphoma of the BrainSeptember 28th, 2020
‘Encouraging’ Responses Seen with Durvalumab plus R-CHOP in DLBCLJune 17th, 2019
Join now to see all

Integrative approach to identify genomic features that shape the immune landscape and predict immunotherapy response in diffuse large B cell lymphomaUNIVERSITY OF CHICAGO2023–2028
Development of antigen multimers for CAR T cell detection and functional profilingUNIVERSITY OF CHICAGO2023–2025